• Elicera Therapeutics received a Chinese notice of allowance for a patent covering its ELC-401 CAR T-cell therapy candidate for glioblastoma.
• The patent covers the IL-13Rα2-binding component, with protection through 2041; formal grant is expected shortly.
• Corresponding applications were previously allowed in the United States and granted in Japan, expanding protection across three major pharmaceutical markets.
• A previously granted Chinese patent covers the candidate’s iTANK platform, designed to stimulate immune responses against additional tumor targets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicera Therapeutics AB published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.